Literature DB >> 1573438

A chronic disease score from automated pharmacy data.

M Von Korff1, E H Wagner, K Saunders.   

Abstract

Using population-based automated pharmacy data, patterns of use of selected prescription medications during a 1 year time period identified by a consensus judgement process were used to construct a measure of chronic disease status (Chronic Disease Score). This score was evaluated in terms of its stability over time and its association with other health status measures. In a pilot test sample of high utilizers of ambulatory health care well known to their physicians (n = 219), Chronic Disease Score (CDS) was correlated with physician ratings of physical disease severity (r = 0.57). In a second random sample of patients (n = 722), its correlation with physician-rated disease severity was 0.46. In a total population analysis (n = 122,911), it was found to predict hospitalization and mortality in the following year after controlling for age, gender and health care visits. In a population sample (n = 790), CDS showed high year to year stability (r = 0.74). Based on health survey data, CDS showed a moderate association with self rated health status and self reported disability. Unlike self-rated health status and health care utilization, CDS was not associated with depression or anxiety. We conclude that scoring automated pharmacy data can provide a stable measure of chronic disease status that, after controlling for health care utilization, is associated with physician-rated disease severity, patient-rated health status, and predicts subsequent mortality and hospitalization rates. Specific methods of scoring automated pharmacy data to measure global chronic disease status may require adaptation to local prescribing practices. Scoring might be improved by empirical estimation of weighting factors to optimize prediction of mortality and other health status measures.

Entities:  

Mesh:

Year:  1992        PMID: 1573438     DOI: 10.1016/0895-4356(92)90016-g

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  259 in total

1.  Initial treatment choice in depression: impact on medical expenditures.

Authors:  E T Edgell; T R Hylan; J R Draugalis; S J Coons
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

2.  Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer.

Authors:  L Penberthy; S M Retchin; M K McDonald; D K McClish; C E Desch; G F Riley; T J Smith; B E Hillner; C J Newschaffer
Journal:  Health Care Manag Sci       Date:  1999-07

3.  High-risk antimicrobial prescriptions among ambulatory patients on warfarin.

Authors:  M A Lane; S T Devine; J R McDonald
Journal:  J Clin Pharm Ther       Date:  2011-04-24       Impact factor: 2.512

4.  Preventing cognitive decline in older African Americans with mild cognitive impairment: design and methods of a randomized clinical trial.

Authors:  Barry W Rovner; Robin J Casten; Mark T Hegel; Benjamin E Leiby
Journal:  Contemp Clin Trials       Date:  2012-03-02       Impact factor: 2.226

5.  Improved comorbidity adjustment for predicting mortality in Medicare populations.

Authors:  Sebastian Schneeweiss; Philip S Wang; Jerry Avorn; Robert J Glynn
Journal:  Health Serv Res       Date:  2003-08       Impact factor: 3.402

6.  Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database.

Authors:  Marc Dorais; Diana Chirovsky; Baishali Ambegaonkar; Vasilisa Sazonov; Glenn Davies; Susan Grant; Jacques Lelorier
Journal:  Can J Cardiol       Date:  2010 Aug-Sep       Impact factor: 5.223

7.  Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

Authors:  Edeltraut Kröger; Rob van Marum; Patrick Souverein; Toine Egberts
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

8.  Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease.

Authors:  Marie-Christyne Cyr; Marie-France Beauchesne; Catherine Lemière; Lucie Blais
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

9.  Characteristics of patients initiating teriparatide for the treatment of osteoporosis.

Authors:  S A Foster; K A Foley; E S Meadows; J A Johnston; S Wang; G M Pohl; S R Long
Journal:  Osteoporos Int       Date:  2007-08-21       Impact factor: 4.507

10.  Case-mix adjusting performance measures in a veteran population: pharmacy- and diagnosis-based approaches.

Authors:  Chuan-Fen Liu; Anne E Sales; Nancy D Sharp; Paul Fishman; Kevin L Sloan; Jeff Todd-Stenberg; W Paul Nichol; Amy K Rosen; Susan Loveland
Journal:  Health Serv Res       Date:  2003-10       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.